Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The CHMP recommends authorizing Sanofi's (SNY) Enjaymo as a treatment for hemolytic anemia in patients with cold agglutinin disease (CAD). The CHMP endorses SNY's RSV vaccine for use in infants.

Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia

ISSOIRE, France--(BUSINESS WIRE)-- #digitalhealth--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced the completion of the development of SoloSmart® today, on the opening of the EASD (European Association for the Study of Diabetes) annual meeting in Stockholm, Sweden. SoloSmart® is fully compatible with the pharmaceutical group's SoloStar® injection pens. The result of

BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD

CHMP recommends approval of Beyfortus ® (nirs e vimab ) for prevention of RSV disease in infants

Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Novartis

Investors might want to take a look at Euroapi S.A. ( XPAR:EAPI , Financial), a Paris-based firm that is a spin-off of Sanofi ( SNY , Financial).

Results for Sanofi Spin-Off Good Omen for Sandoz Generics

Since 2019, scientific communities have been extensively studying the consequences of the active ingredient ranitidine in ZANTAC, and no evidence of harm to consumers has been found. The first trial involving Sanofi as a defendant is scheduled for February 2023.

Sanofi: A Nightmarish August To Take Advantage Of

Dupixent ® (dupilumab) l ate-breaking Phase 3 d ata at EADV 2022 s howed s ignificant i mprovements in signs and symptoms of p rurigo n odularis

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

Sanofi (NASDAQ:SNY ) Citi's 17th Annual BioPharma Conference September 7, 2022 2:40 PM ET Company Participants Bill Sibold - EVP, Sanofi Genzyme; President Sanofi NA, Sanofi SA Conference Call Participants Peter Verdult - Citi Peter Verdult Okay. So good afternoon, everyone.

Sanofi (SNY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)

The appointment of Societe Generale's boss Frederic Oudea as non-executive chairman of Sanofi will be proposed at the next shareholders meeting of the French drugs group, Sanofi said on Monday.

Frederic Oudea to become Sanofi's non-executive chairman

Late- b reaking Dupixent ® (dupilumab) d ata at ERS 2022 s how consistent e fficacy and safety profile for u p to t wo y ears in c hildren a ged 6 to 11 y ears with m oderate-to-severe a sthma

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Press Release: Evolution of the Board of Directors

GlaxoSmithKline

Merck

Morgan Stanley

Novavax

Pfizer

It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn medication Zantac.

This Overlooked Danger Could Tank Big Pharma Stocks

The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme

Xenpozyme TM ( olipudase alfa- rpcp ) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Press Release: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)

Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.

Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag

FDA grants priority review to e fanesoctocog alfa for people with hemophilia A

Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A

This recommendation may help reduce the risk of the flu and flu-related complications in this high-risk population Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine) are both proven to help prevent more cases of flu in older adults compared to a standard-dose vaccine as assessed in randomized controlled trials1,2 In real-world evidence, they also demonstrated a reduction in flu-related complications.3,4 BRIDGEWATER, N.J. , Aug. 26, 2022 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) has published the updated Advisory Committee on Immunization Practices (ACIP) guidance granting preferential recommendation for specific flu vaccines in people age 65+ in its Morbidity and Mortality Weekly Report (MMWR), a journal highlighting the latest in public health news and communicating recommendations derived from science-based research.5  Sanofi's Fluzone ® High-Dose Quadrivalent (Influenza Vaccine) and Flublok ® Quadrivalent (Influenza Vaccine) were among the flu vaccines preferentially recommended by the CDC ACIP for adults 65+.

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

Sanofi's recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines.

Analysis-Meagre medicine cabinet leaves Sanofi unloved

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Is Sanofi A Buy, Despite Recent Stumbles?

Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Sanofi's run of bad luck continued Wednesday after the company scrapped a failed breast cancer drug, leading Sanofi stock to crumble. The post Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug appeared first on Investor's Business Daily.

Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to five drug targets. The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process mo

Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Sanofi's finance chief said on Wednesday that a decline in the French company's share price in response to litigation threats and a cancer drug development setback was strongly exaggerated and posed a buying opportunity for savvy investors.

Sanofi CFO says stock price pummelling grossly overdone

Sanofi provides u pdate on amcenestrant clinical development program

Press Release: Sanofi provides update on amcenestrant clinical development program

Haleon PLC

Johnson & Johnson

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

News for Sanofi Stock (SNY)